Evogene (EVGN)
(Delayed Data from NSDQ)
$0.65 USD
+0.03 (4.02%)
Updated Apr 29, 2024 03:58 PM ET
After-Market: $0.66 +0.01 (1.51%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Evogene Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 6 | 2 | 1 | 1 | 1 |
Cost Of Goods | 2 | 1 | 1 | 1 | 0 |
Gross Profit | 4 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 28 | 31 | 25 | 22 |
Income After Depreciation & Amortization | -27 | -27 | -31 | -25 | -21 |
Non-Operating Income | 1 | 1 | 2 | 2 | 3 |
Interest Expense | 1 | 3 | 1 | 3 | 1 |
Pretax Income | -26 | -30 | -30 | -26 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -2 | -3 | -3 | -3 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -26 | -30 | -30 | -26 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -24 | -27 | -28 | -23 | -18 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -24 | -29 | -22 | -18 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 2 | 3 | 3 |
Income After Depreciation & Amortization | -27 | -27 | -31 | -25 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 45.69 | 41.21 | 40.43 | 28.16 | 25.75 |
Diluted EPS Before Non-Recurring Items | -0.52 | -0.65 | -0.69 | -0.83 | -0.70 |
Diluted Net EPS (GAAP) | -0.52 | -0.65 | -0.69 | -0.83 | -0.70 |
Fiscal Year end for Evogene Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.58 | 3.77 | 0.65 | 0.64 |
Cost Of Goods | NA | 0.40 | 0.51 | 0.46 | 0.32 |
Gross Profit | NA | 0.18 | 3.26 | 0.19 | 0.32 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.81 | 7.44 | 8.10 | 7.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.63 | -4.18 | -7.91 | -6.80 |
Non-Operating Income | NA | 0.36 | 0.43 | 0.39 | 0.31 |
Interest Expense | NA | 0.07 | 0.11 | 0.25 | 0.54 |
Pretax Income | NA | -7.34 | -3.86 | -7.76 | -7.03 |
Income Taxes | NA | 0.00 | -0.01 | 0.02 | -0.05 |
Minority Interest | NA | -0.74 | 0.13 | -0.76 | -0.71 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.34 | -3.86 | -7.78 | -6.98 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -6.60 | -3.98 | -7.02 | -6.27 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 50.59 | 48.92 | 41.64 | 41.49 |
Diluted EPS Before Non-Recurring Items | NA | -0.13 | -0.08 | -0.17 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.12 | -0.08 | -0.17 | -0.15 |